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Malaria: can we mention the e-word yet?
It’s World Malaria Day (April 25) and the theme is 
“End malaria for good”. If I’m not mistaken, that 
means eradication. In one of the ﬁ rst Comment pieces 
The Lancet Global Health ever published, Jenny Liu and 
colleagues asked “Is it possible? Is it worth it? Should we 
do it?” and the community is still divided. 
At the annual meeting of the Consortium of 
Universities for Global Health in San Francisco earlier this 
month, the director of WHO’s Global Malaria Programme, 
Pedro Alonso, was distinctly circumspect about current 
prospects. He noted that the ﬁ rst Global Malaria 
Eradication Programme, launched at the World Health 
Assembly in 1955, produced quick successes but was 
ultimately doomed because of a failure to heed history, 
to do suﬃ  cient research, and to listen to technical advice. 
Eradication had become a “belief system”. He is evidently 
careful not to let it become one today (note the absence 
of the e-word in his programme’s title).
On Liu and colleagues’ question of whether eradication 
was possible, Alonso referred to the three classic indicators 
of “eradicability”: an eﬀ ective intervention to interrupt 
transmission; practical diagnostic tools; and reliance 
on human beings for the life cycle of the disease agent 
(ie, there being no other vertebrate reservoir). All is not 
straightforward for malaria. Although there are eﬀ ective 
interventions (particularly insecticide-treated nets 
[ITNs], indoor residual spraying [IRS], and artemisinin 
combination therapies), diagnostics are more elusive—the 
gold-standard microscopy and the more accessible rapid 
diagnostic tests both have quality and cost issues. Finally, 
although four of the ﬁ ve Plasmodium species have no 
other vertebrate hosts, P knowlesi—the dominant species 
in some parts of southeast Asia—also infects macaques.
So there are technical challenges. But, with commitment 
and consensus, these are not insurmountable in Alonso’s 
cautious opinion. Endorsement at the World Health 
Assembly last year of the Global Technical Strategy 
for Malaria was a vital step forward in this regard. The 
strategy’s ﬁ rst “pillar” is to ensure universal access to 
malaria prevention, diagnosis, and treatment. And 
with one in four children in sub-Saharan Africa still 
living in a household with no ITN or IRS, and 60 million 
infections per year going untreated, there is substantial 
room for improvement. Keen to demonstrate how 
much improvement can happen in just 15 years, Alonso 
pointed to the fact that the number of annual deaths 
was almost twice as high in 2000 as in 2015, that long-
lasting ITNs and IRS did not even exist in 2000, and there 
was widespread chloroquine resistance and next to no 
alternatives in the pipeline. As was revealed last week, 
2015 was also the ﬁ rst year in which any WHO Region 
(Europe) had seen zero cases of malaria.
With this success in mind, the strategy’s second pillar 
is to accelerate eﬀ orts towards malaria-free status 
within countries (elimination), setting a 2030 target to 
eliminate the disease in at least 35 new countries, and to 
prevent its re-establishment. Looking at recent progress 
again, there were less than ﬁ ve countries with fewer 
than 10 cases per year in 2000, but more than 20 last 
year. 25 countries are aiming for elimination by 2020, 
including Bhutan, whose case study we published in last 
month’s issue. That study showed that malaria burden 
fell substantially between 2006 and 2014, largely owing 
to high coverage of long-lasting ITNs. Challenges to the 
maintenance of malaria-free status will be importation 
of malaria, especially from India, and the cost of 
continued ITN and IRS coverage. 
Cost is indeed an issue. Alonso estimated that 
ﬁ nancing will need to triple over the next 15 years if the 
Global Technical Strategy’s targets are to be reached. So 
“Is it worth it?” Another of the key elements of a disease’s 
eradicability is its public health importance, and, for 
malaria, this is undeniable. There were 214 million new 
cases of malaria in 2015 and 438 000 deaths, and the 
disease remains the second greatest cause of death in 
sub-Saharan Africa (after HIV/AIDS).
Finally, should we do it? Or, as others argue, is it better 
simply to control it to a level at which it is no longer a 
public health concern? Alonso had a response ready for 
this very question in San Francisco: “Should we have had 
that aspiration in the USA?” The concept of Florida and 
Texas remaining malarious, at some low level, in the 
21st century is inconceivable. Why should sub-Saharan 
Africa be denied the ambition of being malaria-free? 
Alonso was clear: we’re not planning eradication at this 
stage, but, by 2030, it is something we should be very 
serious about contemplating once again.
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